CClinicalTrials.gg
CompletedNCT05342077VR-RTUpdated Apr 4, 2025

Virtual Reality-Reward Training for Anhedonia

A Phase 1 interventional study of Virtual Reality-Reward Training (VR-RT) and Virtual Reality-Memory Training (VR-MT) in Positive Affect and Depression, sponsored by University of California, Los Angeles. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-04.

Sponsored by University of California, Los Angeles · Phase 1, Interventional, and Treatment

Phase
Phase 1
Study type
Interventional
Enrollment
59
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to compare the effects of Virtual Reality-Reward Training (VR-RT) with an active control condition, Virtual Reality-Memory Training (VR-MT), on positive affect and other clinical symptoms.

VR-Reward Training is a novel intervention aimed at enhancing savoring of positive experiences among individuals with depression and low positive affect through guided imaginal recounting following immersion in positive VR experiences.

Target enrollment is 80 male and female participants with low positive affect, depression, and impaired functioning, who are at least 18 years old, who will be randomly assigned to 7 weeks of either Virtual Reality-Reward Training (VR-RT) or Virtual Reality-Memory Training (VR-MT). Participants will complete in-person VR sessions, laboratory assessments, self-report questionnaires as part of the study.

The total length of participation is around 3 months.

Read the detailed description

Anhedonia, or loss of interest and pleasure in usual activities, has been relatively resistant to pharmacological and psychological treatments in the context of anxiety and depression. Newer treatments that focus upon positivity or reward sensitivity have shown promising results.

The purpose of the current randomized controlled trial is to compare the effects of Virtual Reality-Reward Training (VR-RT) with an active control condition, Virtual Reality-Memory Training (VR-MT), on positive affect and other clinical symptoms. Virtual Reality-Reward Training is designed to augment reward sensitivity in individuals with depression and low positive affect. Targets include behavioral, cognitive, and self-report indices of reward anticipation and initial response to reward. Specificity of target engagement is assessed by comparison with Virtual Reality-Memory Training, designed to improve memory.

Targets and clinical outcomes are assessed at baseline (Week 1) and either weekly or at mid-treatment (Week 3), post-treatment (Week 7), and follow-up (Week 12). Statistical models evaluate whether change in outcomes and change in target measures are greater as a result of Virtual Reality-Reward Training compared to Virtual-Reality-Memory Training and whether changes in target measures correlate with changes in outcome measures.

Target enrollment is 80 male and female participants with low positive affect, depression, and impaired functioning, who are at least 18 years old, who will be randomized to Virtual Reality-Reward Training or Virtual-Reality Memory Training, each comprising 7 individual virtual reality training sessions over the course of 7 weeks.

Participants will complete laboratory tests and self-report questionnaires as part of the study. Total length of participation is around 3 months.

02

Conditions studied

  • Positive Affect
  • Depression

Browse trials for

03

In context

Anhedonia

119 studies on the registry are indexed under Anhedonia; 44 are open to participants now.

This study's enrollment of 59 is below the median of 70 across 99 interventional studies indexed under Anhedonia.

Browse Anhedonia studies →

Lead sponsor

University of California, Los Angeles is the lead sponsor of 1,142 studies on the registry; 192 are open to participants now.

Of its 91 completed or terminated interventional studies of FDA-regulated products, 66 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. At least 18 years old
  2. Fluent in written and spoken English
  3. Meet all of the following dimensional score cutoffs:

    1. Score on the DASS-21 depression subscale must be ≥ 11
    2. Score on the PANAS-P of 24 or lower
    3. Score on the SDS of ≥ 6
  4. Willingness to refrain from initiating other psychosocial treatments throughout the duration of the study

Exclusion criteria

Exclusion Criteria:

  1. Lifetime history of bipolar disorder, psychosis, mental retardation, or organic brain damage
  2. Substance use disorder in the past 6 months
  3. Current use of psychotropic medications
  4. Currently pregnant or planning to become pregnant
  5. Self-reported frequent motion sickness
  6. Self-reported seizures within the last year and/or a diagnosis of epilepsy
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
59 participants (actual)

Study arms

  • Experimental
    Virtual Reality-Reward Training (VR-RT)

    7 sessions of positive VR immersion and positive memory specificity training exercises designed to savor rewarding features of immersion followed by memory specificity training exercises to savor rewarding features of autobiographical memory.

    Behavioral: Virtual Reality-Reward Training (VR-RT)

  • Active comparator
    Virtual Reality-Memory Training (VR-MT)

    7 sessions of neutral VR immersion and neutral memory specificity training exercises, designed to train memory of objective non-emotional stimuli followed by memory exercises to neutral autobiographical memories.

    Behavioral: Virtual Reality-Memory Training (VR-MT)

Interventions

  • BehavioralVirtual Reality-Reward Training (VR-RT)

    Participants will complete verbal recounting (present-tense, field perspective, positive details) and guided imaginal recounting of positive details for rewarding VR experiences and positive autobiographical memories.

  • BehavioralVirtual Reality-Memory Training (VR-MT)

    Participants will complete verbal recounting (past-tense, observer perspective, objective details) and guided imaginal recounting of neutral details for neutral VR experiences and neutral autobiographical memories.

06

What researchers measure

Primary outcomes

  1. Depression, Anxiety, and Stress Scales (DASS-21)

    Reported symptoms of depression (score range: 0-21), anxiety (score range: 0-21), and stress (score range: 0-21), higher scores indicate higher severity and frequency.

    Time frame: Change from baseline to follow-up (Week 12)

  2. The Positive Affect and Negative Affect Schedule-Expanded Form (PANAS X) (General Dimensions Scales)

    Change in reported positive affect (general dimensions scale positive affect) and negative affect (general dimension scale negative affect) (score range for each scale: 10-50, higher scores represent higher levels of positive affect or negative affect).

    Time frame: Change from baseline to follow-up (Week 12)

  3. MASQ-AD 14 Item

    Change in reported anhedonia (score range: 14-70), with higher scores indicating greater anhedonic symptom severity

    Time frame: Change from baseline to follow-up (Week 12)

Secondary outcomes

  1. Behavioral Activation Scale (BAS)

    Change in reported reward sensitivity (score range: 23-92), with higher scores indicating higher reward sensitivity

    Time frame: Change from baseline to follow-up (Week 12)

  2. Work and Social Functioning Scale (WSAS)

    Change in impairment in the following life domains: work (score range: 0-8), home management (score range: 0-8), social leisure (score range: 0-8), private leisure (score range: 0-8) and personal or family relationships (score range: 0-8).

    Time frame: Change from baseline to follow-up (Week 12)

  3. Positive and Negative Affective Schedule (PANAS)

    Change in reported positive affect and negative affect (score range for each scale: 10-50, higher scores indicate higher levels of positive affect or negative affect)

    Time frame: Change from baseline to follow-up (Week 12)

  4. Temporal Experience of Pleasure Scale (TEPS)

    Change in reported anticipatory pleasure (score range: 10-60) and consummatory pleasure (score range: 8-48). Higher scores indicate higher reward responsiveness.

    Time frame: Change from baseline to follow-up (Week 12)

  5. Effort Reward Trade-off Task

    Change in behavioral effort for reward (button presses for points) and experience of reward (happiness ratings). The Effort Reward Trade-off Task is a novel online behavioral task.

    Time frame: Change from baseline to follow-up (Week 12)

  6. Positive Valence Systems Scale (PVSS-21)

    Change in reward anticipation, motivation, and consumption for rewards such as rewards such as food, physical touch, positive feedback, social interactions, hobbies and goals (score range: 21-105). Higher scores (e.g. 105) indicate higher reward responsiveness.

    Time frame: Change from baseline to follow-up (Week 12)

07

Study locations

1 site
  • University of California, Los Angeles
    Los Angeles, California 90095, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05342077
Lead sponsor
University of California, Los Angeles
Responsible party
Michelle Craske (Principal Investigator, University of California, Los Angeles) — Principal investigator
First posted
Apr 22, 2022
Start date
Sep 15, 2022
Primary completion
Mar 14, 2025
Completion
Mar 14, 2025
Last update
Apr 4, 2025

Study contacts

Michelle G Craske, Ph.D
principal investigator · University of California, Los Angeles

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion